Recombinant activated factor seven in acute life-threatening bleeding in neonates: report on three cases and review of literature

J Perinatol. 2006 Nov;26(11):706-13. doi: 10.1038/sj.jp.7211588.

Abstract

Introduction: Acute bleeding of different genesis can be a severe, life-threatening problem in neonatology. Recombinant factor seven (rFVIIa) is known to have unique hemostatic properties in adults and older children.

Case presentation: Three cases of acute life-threatening peri- and postnatal hemorrhage were successfully controlled after the application of fFVIIa. All infants were first treated with vitamin K, fresh-frozen plasma and platelet transfusion.

Conclusion: The cases substantiate other reports that rFVIIa is an effective treatment for acute, refractory and life-threatening bleeding in neonates and premature infants.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Factor VII / therapeutic use*
  • Female
  • Hemorrhage / drug therapy*
  • Hemorrhage / physiopathology
  • Hemostasis / drug effects
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Infant, Premature, Diseases / drug therapy*
  • Male
  • Recombinant Proteins / therapeutic use*
  • Treatment Outcome

Substances

  • Recombinant Proteins
  • Factor VII